Dominari Holdings, Inc.

Is Dominari Holdings, Inc. overvalued or undervalued?

As of November 6, 2023, Dominari Holdings, Inc. is considered risky and overvalued due to poor financial metrics, including a Price to Book Value of 1.87 and a troubling ROCE of -169.94%, with its stock price of 6.33 significantly below its 52-week high of 13.58.

As of 6 November 2023, the valuation grade for Dominari Holdings, Inc. has moved from does not qualify to risky. The company appears to be overvalued given its financial metrics, particularly with a Price to Book Value of 1.87, an EV to Sales ratio of 2.45, and a troubling ROCE of -169.94%. In comparison to peers, Dominari's EV to EBITDA stands at -1.51, while Frequency Therapeutics, Inc. shows a slightly better EV to EBITDA of -1.0091, indicating that Dominari is lagging behind in operational efficiency.<BR><BR>The stock's current price of 6.33 is significantly below its 52-week high of 13.58, suggesting volatility and potential investor concerns. Although specific return data is not available, the lack of positive performance metrics reinforces the notion that Dominari Holdings is overvalued in the current market context.

Is Dominari Holdings, Inc. technically bullish or bearish?

As of September 9, 2025, Dominari Holdings, Inc. shows a mildly bullish technical trend, supported by bullish daily moving averages and weekly MACD, but caution is advised due to a bearish monthly RSI.

As of 9 September 2025, the technical trend for Dominari Holdings, Inc. has changed from bullish to mildly bullish. The weekly MACD indicates a bullish stance, while the monthly MACD is mildly bullish. The daily moving averages are bullish, supporting a positive short-term outlook. However, the monthly RSI is bearish, suggesting potential weakness. The Bollinger Bands are mildly bullish on both weekly and monthly time frames, indicating some upward momentum. The KST shows a mixed signal with weekly mildly bearish and monthly bullish readings. Overall, the technical stance is mildly bullish, but with caution due to the bearish monthly RSI. Multi-period return data is not available for comparison with the S&P 500.

How big is Dominari Holdings, Inc.?

As of Jun 18, Dominari Holdings, Inc. has a market capitalization of 74.11 million and reported net sales of 24.88 million, with a net profit loss of 41.75 million over the latest four quarters. Shareholder's funds are at 39.85 million, and total assets are 48.01 million.

As of Jun 18, Dominari Holdings, Inc. has a market capitalization of 74.11 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 24.88 million for the latest four quarters. However, it also experienced a net profit loss of 41.75 million during the same period.<BR><BR>As of Dec 24, the company's shareholder's funds stood at 39.85 million, while total assets were reported at 48.01 million.

What does Dominari Holdings, Inc. do?

Dominari Holdings, Inc. is a biotechnology company focused on developing small-molecule anti-cancer therapeutics. As of March 2025, it reported net sales of $8 million and a net loss of $32 million, with a market cap of $74.11 million.

Overview:<BR>Dominari Holdings, Inc. is a biotechnology company focused on developing a diverse portfolio of small-molecule anti-cancer therapeutics within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 8 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -32 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 74.11 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 2.37% <BR>Debt Equity: -0.44 <BR>Return on Equity: -83.25% <BR>Price to Book: 1.75<BR><BR>Contact Details:<BR>Address: ONE ROCKEFELLER PLAZA, 11TH FLOOR, NEW YORK NY: 10020 <BR>Tel: 1 347 3217646 <BR>Fax: 1 302 6745266 <BR>Website: http://www.spherix.com/

Should I buy, sell or hold Dominari Holdings, Inc.?

Who are in the management team of Dominari Holdings, Inc.?

As of March 2022, the management team of Dominari Holdings, Inc. includes Dr. Robert Vander Zanden (Independent Chairman), Mr. Anthony Hayes (CEO and multiple officer roles), and Directors Mr. Robert Dudley, Mr. Gregory Blattner, Mr. Tim Ledwick, and Mr. Paul LeMire. The team features a blend of executive leadership and independent directors.

As of March 2022, the management team of Dominari Holdings, Inc. includes the following individuals:<BR><BR>- Dr. Robert Vander Zanden, who serves as the Independent Chairman of the Board.<BR>- Mr. Anthony Hayes, who holds multiple roles as the Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer, and Director.<BR>- Mr. Robert Dudley, who is a Director.<BR>- Mr. Gregory Blattner, who serves as an Independent Director.<BR>- Mr. Tim Ledwick, who is also an Independent Director.<BR>- Mr. Paul LeMire, who serves as an Independent Director.<BR><BR>This team comprises a mix of executive leadership and independent directors, contributing to the governance of the company.